Keryx Biopharmaceuticals (NASDAQ: KERX ) posted its quarterly earnings results on Tuesday. The company reported ($0.09) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.08) by $0.01. Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease.